Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of anlotinib combined with
vinorelbine in the treatment of HER2- advanced breast cancer.